New combo attack on lung cancer: immunotherapy plus local tumor zapping tested in phase 3 trial

NCT ID NCT06840782

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 36 times

Summary

This study is for people with a type of advanced lung cancer that has spread to only a few other places in the body (oligometastatic). The trial tests whether adding local treatments that destroy tumors (like radiation or ablation) to standard first-line immunotherapy can help people live longer. About 124 participants will be randomly assigned to receive either immunotherapy alone or immunotherapy plus these local treatments. The main goal is to see if the combination improves overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Sainte-Catherine

    RECRUITING

    Avignon, Provence-Alpes-Côte d'Azur Region, 84000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Gustave Roussy

    RECRUITING

    Villejuif, Île-de-France Region, 94805, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut de Radiothérapie du Sud de l'Oise

    RECRUITING

    Creil, Hauts-de-France, 60100, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.